Kyle Brown

Oct 22, 2024 | biorxiv.org | Kyle Brown |Todd Gould |Musa I Ajibola

AbstractThe pharmacologically active (R,S)-ketamine (ketamine) metabolite (2R,6R)-hydroxynorketamine (HNK) maintains ketamine's preclinical antidepressant profile without adverse effects. While hypotheses have been proposed to explain how ketamine and its metabolites initiate their antidepressant-relevant effects, it remains unclear how sustained therapeutic actions arise following drug elimination.

Apr 7, 2024 | hudl.com | Kyle Brown

Oops! It looks like AdBlock or a similar tool has prevented this page from loading. Please disable the plugin for all Hudl.com pages and refresh your browser. 56 views | 9:10 | Apr 07, 2024